Global Smoking Cessation and Nicotine De-Addiction Products Market 2018: Key Players Novartis International AG, Pfizer, Inc., Cipla Ltd., Takeda Pharmaceuticals Co. Ltd., NJOY, Inc., Imperial Tobacco Company of India Limited, McNeil AB, and Revolymer Limi

E-cigarette is an electronic nicotine delivery system (ENDS) that is regulated by FDA. E-cigarettes are effective in reducing tobacco related health conditions, while NRTs work best for smoking cessation. E-cigarettes are a potential threat to tobacco based cigarettes, at the same time an opportunity for tobacco manufacturers to enter the new emerging segment catering to the smoking population. Companies such as BAT, Lorillard, Japan Tobacco International, and Philip Morris International (PMI) collaborated with/acquired smaller firms who developed e-cigarettes. This provides major companies in the cigarettes market to compensate for their on-going downward sales of cigarettes. This would give a major boost to the overall smoking cessation and nicotine de-addiction products market. Furthermore, the consideration that e-cigarettes are less harmful than regular cigarettes, no smoke and thus no risk of passive smoking, allowed to use even in no-smoking places, varying nicotine levels and availability in various flavors are some of the major driving factors for e-cigarettes market.

Get Free Sample Copy of This Business Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/134

According to the World Health Organization (WHO), tobacco results in one premature death every six seconds globally. Moreover, in 2015, over 1.1 billion people smoked tobacco globally, with the rate increasing in Africa and Mediterranean Region. Also, tobacco smoking prevalence is the highest in Asia. Therefore, this could be a potential market for the manufacturers in the global smoking cessation and nicotine de-addiction products market. Nicotine being a major addictive component, is harmful to active and passive smokers. Furthermore, concerns regarding the uptake of e-cigarettes by non-smokers considering it as safe for smoking is deterring growth of e-cigarettes in unregulated markets such as India.

Nicotine replacement therapies (NRTs) were the first FDA approved products for smoking cessation treatment. Besides, Buproprion (Zyban) and Varenicline (Chantix) are the two non-nicotine FDA approved products intended for smoking cessation. Electronic nicotine delivery systems (ENDS) are other emerging products aiding in nicotine de-addiction. E-cigarettes can be nicotine-based on non-nicotine based.

Rise in depression and anxiety among the population globally is one of the major factors expected to favor market growth for smoking cessation and nicotine de-addiction products. Rising trend among teenagers for taking up smoking products and e-cigarettes due to increasing peer pressure are further favoring growth of the global smoking cessation and nicotine de-addiction products market. The market is estimated to witness considerable revenue traction over the forecast period, due to increasing lifestyle changes and government initiatives promoting smoking cessation and nicotine de-addiction products in Asia and European countries is in turn expected to support growth of the smoking cessation and nicotine de-addiction products market in the near future.

According to Ministry of Health & Family Welfare (MoHFW), Government of India, every March 9, is celebrated as national no-smoking day, which in turn is expected to favor increase in awareness about smoking cessation and nicotine de-addiction products among the population. This is expected to favor growth of the smoking cessation and nicotine de-addiction products market over the forecast period

Download Free PDF Brochure of This Business Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/134

Some of the major players are Johnson & Johnson Limited, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Cipla Ltd., Takeda Pharmaceuticals Co. Ltd., NJOY, Inc., Imperial Tobacco Company of India Limited, McNeil AB, and Revolymer Limited

Detailed Segmentation:

Global Smoking Cessation and Nicotine De-addiction Products Market, By Product Type:
Nicotine Replacement Therapy
OTC
Nicotine Spray
Nicotine Inhalers
Nicotine Gum
Nicotine Transdermal Patches
Prescription
Nicotine Sublingual Tablets
Nicotine Lozenges
Drugs
Varenicline
Zyban
E-Cigarettes
Modular
Disposable
Rechargeable
Global Smoking Cessation and Nicotine De-addiction Products Market, By Distribution Channel:
Hospital Pharmacies
Online Channel
Retail Pharmacies
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.